Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial ...

Agenus shifts to BOT+BAL in neoadjuvant MSS colon cancer; $85M raise extends runway to 2031. Click here to read this latest ...

The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...

(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross ...

Shares of Agenus AGEN soared nearly 83% on Monday after the biotech announced an oversubscribed private placement of up to ...

Surgeries on the wrong part of the body, medicine administered in the wrong doses, and failures to listen to patients — these ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Slowing Procedure Growth and Tariffs Take Center Stage Just now Live Intuitive Surgical’s (NASDAQ: ISRG) second-quarter ...

A new study from researchers at LSU's Pennington Biomedical Research Center, FMOL Health | Our Lady of the Lake Regional ...

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...

Humanoid robots have performed two surgeries in pigs for the first time, a new development researchers say may be a potential ...